The Parallax View

Home
Archive
About
CD47: Eating Up Cancer and Biobucks
8,500 words on $TRIL $ALXO $IMAB $STTK $OSE $GILD
 • 
The Parallax View
A Little Gift
Biotech tracking excel of 800+ US-listed biotechs
 • 
The Parallax View
$CRTX | Cortexyme
A post-mortem and a look at what’s next
 • 
The Parallax View
Most Popular
View all
The Biotech Investor's Resources
 • The Parallax View
1
You've Been Targeted for Termination
 • The Parallax View
$INFI | Infinity Pharma's bet on PI3K-γ
 • The Parallax View
3
The State of Biotech Today
 • The Parallax View
From Germophobe to Germophile
 • The Parallax View
New
Top
Community
$BNTX | BioNTech: mRNA therapies beyond the COVID-19 vaccine
An exciting approach to auto-immune conditions published in Science shows the broad potential of future mRNA therapies
 • 
The Parallax View
The State of Biotech Today
Our world in charts
 • 
The Parallax View
The Biotech Investor's Resources
Use these to help make $XBI a better place
 • 
The Parallax View
1
Q3 2021 13F Review + Composite Ticker List
Hi Subscriber, It’s been a busy past few weeks and we wanted to make sure we sent some goodies out to you as we wrap up a few more pieces on our end…
 • 
The Parallax View
1
$GLUE | Monte Rosa Therapeutics
Drugging the undruggable, not redrugging the druggable
 • 
The Parallax View
$TLIS | Talis, the Dark Horse of Point-of-Care Testing?
COVID-19 Variant & Flu POCT and the New Normal
 • 
The Parallax View
1
Q2 2021 13F Review
Looking at portfolio changes for RA, Perceptive, Baker, OrbiMed, BVF, EcoR1, Redmile, Opaleye, Ghost Tree
 • 
The Parallax View
The Parallax View
The Parallax View
Finding unloved, undiscovered, and undervalued biotechs

The Parallax View

AboutArchiveSitemap
© 2023 Substack Inc
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing